- Home
- APRE vs COSM Comparison
APRE vs COSM Comparison
Compare APRE & COSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APRE
- COSM
- Stock Information
- Founded
- APRE 2006
- COSM 2009
- Country
- APRE United States
- COSM Greece
- Employees
- APRE N/A
- COSM N/A
- Industry
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- COSM Other Pharmaceuticals
- Sector
- APRE Health Care
- COSM Health Care
- Exchange
- APRE Nasdaq
- COSM Nasdaq
- Market Cap
- APRE 9.7M
- COSM 8.2M
- IPO Year
- APRE 2019
- COSM 2013
- Fundamental
- Price
- APRE $1.65
- COSM $0.43
- Analyst Decision
- APRE Strong Buy
- COSM
- Analyst Count
- APRE 2
- COSM 0
- Target Price
- APRE $15.50
- COSM N/A
- AVG Volume (30 Days)
- APRE 17.1K
- COSM 749.7K
- Earning Date
- APRE 05-20-2025
- COSM 04-16-2025
- Dividend Yield
- APRE N/A
- COSM N/A
- EPS Growth
- APRE N/A
- COSM N/A
- EPS
- APRE N/A
- COSM N/A
- Revenue
- APRE $1,502,581.00
- COSM $54,426,402.00
- Revenue This Year
- APRE N/A
- COSM $28.14
- Revenue Next Year
- APRE N/A
- COSM N/A
- P/E Ratio
- APRE N/A
- COSM N/A
- Revenue Growth
- APRE 157.63
- COSM 1.97
- 52 Week Low
- APRE $1.41
- COSM $0.28
- 52 Week High
- APRE $5.90
- COSM $1.58
- Technical
- Relative Strength Index (RSI)
- APRE 41.84
- COSM 52.13
- Support Level
- APRE $1.67
- COSM $0.40
- Resistance Level
- APRE $1.99
- COSM $0.55
- Average True Range (ATR)
- APRE 0.14
- COSM 0.06
- MACD
- APRE 0.04
- COSM 0.01
- Stochastic Oscillator
- APRE 41.55
- COSM 56.06
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About COSM Cosmos Health Inc.
Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.